BioNTech, the German developer of a widely used mRNA vaccine for the coronavirus, agreed to pay US$800 million (HK$6.24 billion) to buy biotech company Biotheus, a developer of cancer drugs. In a ...

He was a lifelong advocate for vaccines but was cast out by the medical establishment in the UK during Covid for promoting ...

SyVento says bringing the FlexFactory to Poland makes new therapies available to patients in an efficient and high-quality way.

On the other hand, Moderna Inc (NASDAQ: MRNA) posted a surprise profit and higher than expected revenue following the launch ...

BioNTech plans to further investigate the drug’s potential in combination with mRNA vaccines, targeted therapies and ...

Expects to complete enrollment of the 400-participant sentinel cohort for the COVID-19 Phase 2b study in November 2024 Solid financial position enables Vaxart to attain multiple regulatory and ...

Reactogenicity is comparable for simultaneous and sequential administration of mRNA COVID-19 and influenza vaccines.

Most people don't enjoy getting shots for treatments or vaccines. So, researchers are working to create more medicines, such ...

Join the GenScript Biotech Global Forum in London to Navigate the Future of Cell and Gene Therapies. For more information, ...

Most people don’t enjoy getting shots for treatments or vaccines. So, researchers are working to create more medicines, such ...

The newest case is the fifth to bring similar allegations against Moderna in the same court, with three others, all filed Nov ...

A groundbreaking study introduces stable inhalable mRNA treatment using nanoparticles that hold up during nebulization, ...